1. Researchers have developed a pH-dependent anti-CD47 antibody (BC31M4) which selectively binds to tumors under the acidic solid tumor microenvironment.
2. The crystal structure reveals that two histidines located within the CDRs of the light chain directly contribute to the pH-dependent binding of BC31M4.
3. BC31M4 promotes macrophage phagocytosis of tumor cells more potently at acidic-pH than at physiological-pH, and causes minimal side effects with superior PK properties compared to other anti-CD47 antibodies.
The article is generally trustworthy and reliable, as it provides detailed information about the research conducted, including methods used, results obtained, and conclusions drawn from them. The authors also provide evidence for their claims in the form of in vitro assays, studies in xenograft models, and humanized immunocompetent syngeneic mouse models. Furthermore, they discuss potential risks associated with their findings and provide possible solutions for overcoming them.
However, there are some points that could be improved upon in terms of trustworthiness and reliability. For example, while the authors discuss potential risks associated with their findings, they do not provide any evidence or data to support these claims. Additionally, while they mention possible solutions for overcoming these risks, they do not explore any counterarguments or alternative approaches that could be taken instead. Furthermore, while they present both sides of the argument equally in terms of discussing potential risks and solutions for them, they do not provide any evidence or data to back up their claims regarding the efficacy of BC31M4 as an antitumor agent. Finally, there is a lack of discussion regarding potential biases or conflicts of interest that may have influenced the results presented in this article.